CNVVF Stock Chart & Stats
$2.91
-$0.11(-3.51%)
At close: 4:00 PM EST
$2.91
-$0.11(-3.51%)
Day’s Range― - ―
52-Week Range$2.30 - $3.72
Previous CloseN/A
Volume350.00
Average Volume (3M)3.56K
Market Cap
$5.69B
Enterprise Value$6.06K
Total Cash (Recent Filing)$75.03M
Total Debt (Recent Filing)$1.52B
Price to Earnings (P/E)33.5
Beta0.47
Next Earnings
Aug 04, 2026EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend Yield2.55%
Share Statistics
EPS (TTM)0.09
Shares Outstanding1,954,852,000
10 Day Avg. Volume10,328
30 Day Avg. Volume3,561
Financial Highlights & Ratios
PEG Ratio-7.33
Price to Book (P/B)4.36
Price to Sales (P/S)2.66
P/FCF Ratio19.37
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$4.01Price Target Upside37.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)<0.01
Revenue Forecast (FY)$34.51M
Bulls Say, Bears Say
Bulls Say
Consistent Organic Revenue GrowthA multi-year record of >5% organic growth shows durable demand for ConvaTec’s chronic-care consumables and recurring revenue nature. Management’s 6–8% medium-term target and reiterated 2026 guidance support predictable top-line expansion that underpins investment, capacity planning and long-term cash flow.
Sustained Margin ExpansionMaterial operating margin improvement reflects pricing, productivity and scale benefits across its product portfolio. A mid‑20s margin target indicates structural operating leverage that should produce sustainably higher operating cash flow and reinvestment capacity, supporting R&D and capacity spend over coming years.
Strong Cash Generation & Capital ReturnsConsistently high free‑cash conversion and active buybacks/dividend growth demonstrate robust cash generation that finances growth CapEx and shareholder returns. A stated 100% conversion target for 2026 and history of large buybacks provide durable financial flexibility for strategic investments and balance sheet management.
Bears Say
Rising LeverageHigher leverage reduces financial flexibility and increases sensitivity to earnings shocks or rising rates despite management’s net-debt/EBITDA target. With elevated debt funding, the company has less buffer for unexpected costs or prolonged reimbursement headwinds, potentially constraining strategic optionality and raising refinancing risk.
FDA Warning Letter On CAPA/ComplaintsRegulatory deficiencies in quality systems are structural operational risks that can limit market access or require costly remediation. Even without identified product safety issues, resolving CAPA weaknesses demands sustained management attention and investment, and could slow product launches or invite further regulatory scrutiny.
InnovaMatrix Reimbursement Shock & ImpairmentA major reimbursement-driven price collapse illustrates vulnerability of newly acquired, reimbursement-dependent assets to payer decisions. The impairment and ongoing channel/legal uncertainty reduce returns on acquisition spend and highlight M&A and product pricing risks that can structurally depress margins and complicate medium-term growth assumptions.
ConvaTec News
CNVVF FAQ
What was ConvaTec’s price range in the past 12 months?
ConvaTec lowest stock price was $2.30 and its highest was $3.72 in the past 12 months.
What is ConvaTec’s market cap?
ConvaTec’s market cap is $5.69B.
When is ConvaTec’s upcoming earnings report date?
ConvaTec’s upcoming earnings report date is Aug 04, 2026 which is in 13 days.
How were ConvaTec’s earnings last quarter?
ConvaTec released its earnings results on Feb 24, 2026. The company reported $0.097 earnings per share for the quarter, missing the consensus estimate of $0.1 by -$0.003.
Is ConvaTec overvalued?
According to Wall Street analysts ConvaTec’s price is currently Undervalued.
Does ConvaTec pay dividends?
ConvaTec pays a Semiannually dividend of $0.054 which represents an annual dividend yield of 2.55%. See more information on ConvaTec dividends here
What is ConvaTec’s EPS estimate?
ConvaTec’s EPS estimate is 0.08.
How many shares outstanding does ConvaTec have?
ConvaTec has 1,954,852,000 shares outstanding.
What happened to ConvaTec’s price movement after its last earnings report?
ConvaTec reported an EPS of $0.097 in its last earnings report, missing expectations of $0.1. Following the earnings report the stock price went up 10.04%.
Which hedge fund is a major shareholder of ConvaTec?
Currently, no hedge funds are holding shares in CNVVF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ConvaTec Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.01 (37.75% Upside)
$4.01 (37.75% Upside)
Insider Transactions
Bought Shares
Worth $201.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.50%
12-Months-Change
Fundamentals
Return on Equity
2.55%
Trailing 12-Months
Asset Growth
0.16%
Trailing 12-Months
Company Description
ConvaTec
ConvaTec Group Plc operates as a global medical technology company, specializing in the creation, production, and worldwide distribution of a diverse array of healthcare products. Its offerings span critical areas, including advanced wound care, where it provides specialized dressings and skin care items for managing acute and chronic wounds that arise from conditions like diabetes, immobility, venous disease, traumatic injuries, burns, or surgical recovery. The company is also a key provider in ostomy care, delivering essential devices, accessories, and support services for individuals living with a stoma due to conditions such as colorectal cancer, inflammatory bowel disease, bladder cancer, and obesity. Beyond wound and ostomy solutions, ConvaTec's portfolio extends to continence and critical care. This includes intermittent urinary catheters and related products designed to assist individuals with urinary continence issues stemming from spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders. They also furnish equipment for intensive care units and hospital settings, alongside advanced systems for managing acute fecal incontinence and monitoring urine output and intra-abdominal pressure. Additionally, ConvaTec supplies various disposable medical devices, such as wound drainage systems, urine collection bags, airway management tools, gastroenterology tubes, and securement devices. The company manufactures disposable infusion sets for insulin pumps used in diabetes treatment, as well as for other continuous infusion therapies. These products reach pharmacies, hospitals, and both acute and post-acute healthcare providers directly, or through a network of distributors and wholesalers, catering to healthcare professionals, patients, and other manufacturers. Established in 1978, ConvaTec Group Plc is headquartered in Reading, United Kingdom.
CNVVF Stock 12 Month Forecast
Average Price Target
$4.01
▲(37.75% Upside)
Technical Analysis
Ownership Overview
0.20% Insiders
13.24% Mutual Funds
<0.01% Other Institutional Investors
78.72% Public Companies and
Individual Investors